RDX-022
- Generic Name
- RDX-022
A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2019-12-26
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 60
- Registration Number
- NCT03018067
- Locations
- 🇺🇸
Capital Nephrology Associates, PA, Cary, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath